New pill targets brain tumors with IDH mutations
NCT ID NCT02481154
First seen Feb 20, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This early-phase trial tested an oral drug called AG-881 in 95 adults with advanced gliomas (a type of brain tumor) that have an IDH1 or IDH2 mutation. The main goals were to check the drug's safety, find the best dose, and see if it shrinks tumors. The study was completed, but because lifelong monitoring and potential follow-up treatments are typical for glioma, this is considered disease control rather than a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 75390, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
UCLA Oncology Center
Los Angeles, California, 90024, United States
-
UT Southwestern Medical Center
Dallas, Texas, 77030, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.